Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases. Based in the United States, the company utilizes its proprietary FORCE platform to deliver oligonucleotide therapeutics directly to muscle tissue. The platform conjugates antibodies to short DNA or RNA molecules, enabling targeted delivery to degrade disease-causing RNA. Dyne's clinical pipeline includes lead programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Additionally, the company is advancing preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease, as well as exploring treatments for cardiac and metabolic muscle diseases.
